News
SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for cla...
The results of the SERENA-2 trial of AstraZeneca’s oral selective estrogen receptor degrader (SERD) camizestrant, reported at the SABCS congress this week, could restore confidence in the m
